Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced initiation of a Phase 1 clinical trial (NCT07414940) evaluating Actinium ...

The University College London (UCL) sponsored study evaluates safety, tolerability and radiation dosimetry of an investigational alpha-emitting PSMA-targeted radiopharmaceutical therapy, building ...

Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...

DEAR DR. ROACH: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn’t successful. I was told that surgery after ...

Dear Dr. Roach: About six years ago, I was diagnosed with prostate cancer. I chose to have a high-intensity focused ultrasound (HIFU), which ultimately wasn't successful. I was told that surgery after ...

When I had my prostate removed in September 2023, I believed the worst was behind me. After months of tests, scans and ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Federal officials may remove warnings on testosterone therapy drugs about heart and prostate risks, which could expand access ...

Suffering from prostate cancer or benign prostatic hyperplasia (BPH) is not the end of a relationship. Technology and sexologists offer solutions to maintain erections and orgasms, even if ejaculation ...

HENGRUI PHARMA (01276.HK) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical, has received the "Notice of ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients ...